Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of pasireotide LAR in
combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary
neuroendocrine Tumors (NET).